Table 1 Published studies on “CP7_E2alf” and their topics.

Vaccine design and construction

Laboratory protocols for chimera design

[40]

Construction of the chimera, sequence analysis, initial in vitro and in vivo tests

[39]

Genetic stability

Stability over cell culture passages, search for recombinants in co-infection studies, stability in vivo

[18]

Safety

Assessment of shedding through feces, urine and semen, dissemination

[10]

Dissemination, onset of antibody responses, diagnostic tests

[48]

Innocuousness and safety in target and non-target species

[26]

Detection and dissemination of vaccine virus

[24]

Efficacy

Efficacy in the presence of MDA

[15]

Efficacy in the presence of BVDV-1 antibodies, DIVA

[11]

Efficacy in MDA negative piglets, intramuscular and oral vaccination with challenge at 14 dpv with CSFV “Koslov”

[29]

Efficacy in piglets with MDA, intramuscular (3 weeks/6 weeks) and oral vaccination (6 weeks), challenge 14 dpv with CSFV “Koslov”

[13]

Efficacy against different genotypes of CSFV, intramuscular and oral vaccination (domestic pigs and wild boar), challenge 14 dpv/21 dpv

[6]

Efficacy after intramuscular vaccination and DIVA (comparative trial with different chimeras), challenge 7 and 14 dpv with CSFV “Koslov”

[12]

Efficacy in piglets with C-strain derived MDA (5 weeks/8 weeks), challenge with CSFV “Koslov” 14 dpv

[38]

Duration of immunity study, intramuscular and oral vaccination, challenge 6 months post vaccination with CSFV “Koslov”

[17]

Efficacy after oral vaccination (comparative trial with different chimeras), challenge 14 and 21 dpv

[4]

Onset of immunity and vaccine dose, efficacy study, genetic stability, intramuscular and oral vaccination

[27, 28]

Efficacy (and safety) of oral immunization of wild boar

[25]

DIVA diagnostics

Development and validation of an E^rns -specific double-antigen ELISA

[34]

Design and evaluation of an E^rns ELISA

[33]

Evaluation of a discriminatory CSFV E^rns ELISA in an inter-laboratory trial

[37]

Differentiation of CSFV infection and “CP7_E2alf” vaccination using a multiplex microsphere immunoassay

[53]

Design of two E^rns antibody ELISAs

[1]

Inter-laboratory comparison test of possible discriminatory assays

[45]

Development of a RT-PCR system for vaccine/field virus discrimination (genetic DIVA)

[31]

Development of a RT-PCR system for vaccine/field virus discrimination (genetic DIVA)

[27]

Field study

Oral vaccination of wild boar in faunistic hunting farms in Umbria, bait vaccination, comparative study in captive wild boar, vaccine stability

[16]

Supplemental studies

Kinetics of MDA upon intramuscular vaccination

[44]

Cytokine and immunoglobulin isotype profiles

[42]

Challenge 2 days after oral immunization, cytokine profiles

[41]